K I Pritchard

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

I. Andrulis, F. O'Malley, D. Tu, 2009, Journal of the National Cancer Institute.

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.

A Gafni, A Laupacis, R S Hayward, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12).

D. Tu, V. Bramwell, K. Pritchard, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

D. Tu, V. Bramwell, B. Norris, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).

L. Murphy, P. Watson, D. Tu, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.